Ana Barroso
Research Subjects
Ana Barroso has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- José Carlos Machado
Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal
2 shared publications - Sara Conde
Pulmonology Department, Centro Hospitalar Vila Nova de Gaia e Espinho, Portugal
2 shared publications - Agostinho Sanches1 shared publication
Ana Linhas
1 shared publication- Ana Rita Gigante
Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho
1 shared publication - Antónia Furtado
Pathology Department, Centro Hospitalar Vila Nova de Gaia/Espinho
1 shared publication
Latest Publications
- Open Access
- 30 May 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (3) , 305-306
Lung cancer and breast metastasis: A rare and atypical presentation
- 30 May 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (3) , 305-306
Open AccessLung cancer and breast metastasis: A rare and atypical presentation
- 22 September 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista do Grupo de Estudos do Cancro do Pulmão
- Vol. 19 (1) , 17-24
Carcinoma Pulmonar Não Pequenas Células metastático tratado com imunoterapia + quimioterapia: um caso de resposta dissociada?
A avaliação de resposta ao tratamento sistémico no CPNPCm pode ser desafiante, particularmente quando se utiliza imunoterapia, devido à possibilidade de padrões atípicos de resposta. Descrevemos um caso de adenocarcinoma pulmonar metastático sob imunoterapia e quimioterapia com aparente resposta dissociada em nódulo pulmonar, cuja biópsia da lesão não respondedora revelou um diagnóstico histológico diferente do tumor primário. Quando existe discrepância no tipo de resposta ao tratamento sistémico de duas lesões alvo diferentes, é importante ponderar a possibilidade de se tratar de um segundo tumor primário. A confirmação do diagnóstico histopatológico e/ou molecular é crucial para o (re)estadiamento, orientação de tratamento e prognóstico do doente.
- 22 September 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista do Grupo de Estudos do Cancro do Pulmão
- Vol. 19 (1) , 17-24
Carcinoma Pulmonar Não Pequenas Células metastático tratado com imunoterapia + quimioterapia: um caso de resposta dissociada?
A avaliação de resposta ao tratamento sistémico no CPNPCm pode ser desafiante, particularmente quando se utiliza imunoterapia, devido à possibilidade de padrões atípicos de resposta. Descrevemos um caso de adenocarcinoma pulmonar metastático sob imunoterapia e quimioterapia com aparente resposta dissociada em nódulo pulmonar, cuja biópsia da lesão não respondedora revelou um diagnóstico histológico diferente do tumor primário. Quando existe discrepância no tipo de resposta ao tratamento sistémico de duas lesões alvo diferentes, é importante ponderar a possibilidade de se tratar de um segundo tumor primário. A confirmação do diagnóstico histopatológico e/ou molecular é crucial para o (re)estadiamento, orientação de tratamento e prognóstico do doente.
- Open Access
- 30 July 2022
- Published by Taylor & Francis in Pulmonology
- Vol. 28 (4) , 315-316
KIF5B-MET fusion variant in non-small cell lung cancer
- 30 July 2022
- Published by Taylor & Francis in Pulmonology
- Vol. 28 (4) , 315-316
Open AccessKIF5B-MET fusion variant in non-small cell lung cancer
- 1 January 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (1) , S1300-S1301
P3.02c-043 Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge
- 1 January 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (1) , S1300-S1301
P3.02c-043 Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge
- 17 January 2016
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 11 (6) , 854-858
Role of epidermal growth factor mutational status for distinction between recurrent lung cancer and second primary lung cancer: case report
In a patient with previous radically treated lung adenocarcinoma, the detection of a new lung cancer raises the question whether recurrence or a second primary lung cancer is involved. Current criteria for differentiating multiple lung tumors lack a biologic and molecular basis and may lead to misclassification with impact on survival. We report the case of a female patient with a recent diagnosis of lung adenocarcinoma and a previous lung adenocarcinoma submitted to curative surgical therapy 4 years before. As both lesions were resected, were of the same histologic subtype and presented the same immunohistochemistry profile; we decided to perform mutational analysis of the epidermal growth factor (EGFR) gene to differentiate between recurrence and second primary lung cancer. The EGFR gene was screened for mutations in exons 18, 19, 20 and 21 using direct sequencing of polymerase chain reaction products in DNA obtained from paraffin preserved cells from both tumors. Mutational analysis of the EGFR gene, revealed different mutations in each tumor (both on exon 19) allowing the confirmation of the diagnosis of two metachronous primary lung cancers. In this patient, mutational analysis of the EGFR gene was superior to histologic and immunohistochemistry characterization in differentiating between recurrent lung cancer and second primary lung cancer; allowing confirmation of the diagnosis of two metachronous primary lung cancers.
- 17 January 2016
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 11 (6) , 854-858
Role of epidermal growth factor mutational status for distinction between recurrent lung cancer and second primary lung cancer: case report
In a patient with previous radically treated lung adenocarcinoma, the detection of a new lung cancer raises the question whether recurrence or a second primary lung cancer is involved. Current criteria for differentiating multiple lung tumors lack a biologic and molecular basis and may lead to misclassification with impact on survival. We report the case of a female patient with a recent diagnosis of lung adenocarcinoma and a previous lung adenocarcinoma submitted to curative surgical therapy 4 years before. As both lesions were resected, were of the same histologic subtype and presented the same immunohistochemistry profile; we decided to perform mutational analysis of the epidermal growth factor (EGFR) gene to differentiate between recurrence and second primary lung cancer. The EGFR gene was screened for mutations in exons 18, 19, 20 and 21 using direct sequencing of polymerase chain reaction products in DNA obtained from paraffin preserved cells from both tumors. Mutational analysis of the EGFR gene, revealed different mutations in each tumor (both on exon 19) allowing the confirmation of the diagnosis of two metachronous primary lung cancers. In this patient, mutational analysis of the EGFR gene was superior to histologic and immunohistochemistry characterization in differentiating between recurrent lung cancer and second primary lung cancer; allowing confirmation of the diagnosis of two metachronous primary lung cancers.